Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antibiotics Stewardship Remains Open Question On Capitol Hill

Executive Summary

FDA’s role in the practice of medicine becomes an issue as IDSA’s proposal to spur antibiotic development by coupling small trials with limited use comes late to the antibiotic incentives debate on Capitol Hill.

Advertisement

Related Content

Targeted Antibiotics Could Get Limited Data Approval Option From FDA
Antibiotic Incentives: FDA’s Woodcock Says LPAD Could Be Better Than Exclusivity, But Questions Remain
Orphan Antibiotics? Woodcock Says It May Be Possible If IDSA’s New Pathway Is Implemented
User Fee Package Offers FDA Reforms From A House Wary Of FDA Power
User Fee Package Offers FDA Reforms From A House Wary Of FDA Power
GMP Third-Party Audits Offered In Draft Senate User Fee Legislation
FDA Antibiotic Legislation Should Focus On Criteria, Not Bacteria, Woodcock Says
IPAB Repeal Bill On Way To House Vote
FDA Exploring Limited-Use Approvals For Antibiotics Based On Small Development Programs
Antibiotics Could Get Double Exclusivity Under House Bill; FDA Makes Its Own Moves

Topics

Advertisement
UsernamePublicRestriction

Register

PS054309

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel